Atai stocks.

Real time Atai Life Sciences (ATAI) stock price quote, stock graph, news & analysis.Nov 18, 2022 · (See ATAI stock forecast on TipRanks) SomaLogic . The next Wood pick we’ll look at is a protein biomarker discovery and clinical diagnostics company. SomaLogic operates in what is known as the ... Stock Data; Quote. Stock Data. Quote · Charts · Historical Data. ATA Creativity ... ® Copyright 2023 atai.net.cn ATA Group All rights reserved 沪ICP备14030601号- ...ATAI is down -$0.02 from the previous closing price of $1.14 on volume of 308,405 shares. Over the past year the S&P 500 has risen 15.21% while ATAI is down -62.79%. ATAI lost -$0.46 per share in the over the last 12 months. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Atai Life Sciences (NASDAQ:ATAI) said its majority-owned unit Perception Neuroscience's therapy PCN-101 (R-ketamine) did not meet the main goal of a phase 2a trial for treatment-resistant depression.

ATAI Life Sciences N.V. Common Shares (ATAI) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time After-Hours Live Key Data Bid Price and Ask Price The bid & ask refers to the price... Funding. ATAI Life Sciences has raised a total of. $522.1M. in funding over 11 rounds. Their latest funding was raised on Aug 15, 2022 from a Post-IPO Debt round. ATAI Life Sciences is registered under the ticker NASDAQ:ATAI . Their stock opened with $15.00 in its Jun 17, 2021 IPO. ATAI Life Sciences is funded by 42 investors.Web

Creso Pharma and Red Light Holland entered into a definitive scheme implementation deed to combine businesses and create The HighBrid LabFrom July 5 to July 7, the ARK Genomic Revolution ETF purchased 268,974 shares of ATAI Life Sciences (NASDAQ: ATAI). This was the ETF and Ark Invest’s first purchase of ATAI stock since March 14.

$0.08 (7.69%) Today $1.14 0.02 (1.79%) After Hours About Feed News Earnings Fundamentals There is no chart data available for this period 1d 1w 1m 3m 6m 1y All …On December 2, 2023, the Board appointed Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees pursuant to the Rights Agreement, to serve until …Atai Life Sciences (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. In the first week of the new year, the stock plummeted when the failed results of ATAI's NYC-based subsidiary, Perception Neuroscience's Phase 2a study of proprietary R-ketamine PCN-101 on …ATAI Life Sciences NV’s trailing 12-month revenue is $0.3 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-0.317 per share for the current fiscal year. ATAI Life Sciences NV does not currently pay a dividend.ATAI – ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are 3 stocks that are looking to commercialize psychedelics for medical use. Investors should keep them on their radars as they have massive long-term potential. Norms and regulations in society can change in the span of …

atai Life Sciences has priced its upsized U.S. IPO of 15M common shares (from ~14.3M) at $15.00/share. Expected gross proceeds are $225M. Underwriters' over-allotment is an additional 2.25M shares.Web

Jan 8, 2023 · What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management. Pros and cons to owning his top 5 stocks.

See Full ATAI Report. ATAI stock closed at $1.12 and is down -$0.08 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. ATAI has a poor overall score of 33 meaning the stock holds a better value than just 33% of stocks at its current price.WebNov 29, 2023 · The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions. 4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price.ATAI Life Sciences N.V. Watch Set a price target alert Premarket Last Updated: Nov 15, 2023 8:18 a.m. EST Delayed quote $ 1.2900 0.04 2.79% Before Hours Volume: 2.23K Advanced Charting Volume:... Mar 31, 2023 · Atai Life Sciences ( ATAI 2.80%), a small-cap drugmaker developing psychedelic-based treatments for drug dependency and mental health disorders, posted strong gains during the first four days of ... Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.

Mar 31, 2023 · Atai Life Sciences ( ATAI 2.80%), a small-cap drugmaker developing psychedelic-based treatments for drug dependency and mental health disorders, posted strong gains during the first four days of ... Sep 9, 2022 · Math Over Myth aims to remove the romance and mythology from investing to focus strictly on price movements, mathematics, and technical analysis. Today we focus on ATAI and CMPS. Investing in emerging, disruptive, and speculative sectors of the marketplace doesn’t necessarily need to be a risky endeavor if you approach it with the right ... ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with ...atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights. Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 (a proprietary oral transmucosal film ...Atai Life Sciences has a strong pipeline of drugs for the next 18 months, and will pursue aggressive growth. The company had $335 million in cash as of May 2022, which is roughly 50% of its ...

At Compass’ current market cap of ~$1.1 billion, ATAI has a $200 – 300 million stake in the company. This gives ATAI’s valuation a sort of floor dependent on Compass’ ultimate market cap. It will be just as important for Compass to succeed over the coming months as it will for ATAI’s portfolio companies to perform.WebIn January 2023, atai announced results from the Phase 2a proof-of-concept study evaluating a single IV administration of PCN-101 in patients with treatment-resistant depression across three arms ...

Dec 1, 2023 · View atai Life Sciences NV ATAI investment & stock information. Get the latest atai Life Sciences NV ATAI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ATAI was founded in 2018, and went public this past June through an IPO. The company’s IPO was initially announced with 14.286 million shares going on the market with a price between $13 and $15 ...Jun 15, 2021 · The ATAI IPO will raise around $100 million that the company can add to its already sizeable cash on hand, about $97 billion as of the end of 2020. ATAI stock could be the biggest psychedelic ... Get the latest Butterfly Network Inc (BFLY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.WebAtai Life Sciences (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. In the first week of the new year, the stock plummeted when the failed results of ATAI's NYC-based subsidiary, Perception Neuroscience's Phase 2a study of proprietary R-ketamine PCN-101 on patients with ...ATAI Life Sciences NV (ATAI) stock is trading at $2.17 as of 1:48 PM on Monday, Jul 17, a gain of $0.15, or 7.55% from the previous closing price of $2.02. The stock has traded between $2.00 and $2.20 so far today. Volume today is less active than usual.35,390.15 +117.12(+0.33%) Nasdaq -15.00(-0.11%) Russell 2000 1,807.50 +11.96(+0.67%) Crude Oil 75.54 -1.56(-2.02%) Gold 2,003.00 +10.20(+0.51%) Atai Life Sciences N.V. (ATAI) NasdaqGM -...

The latest atai Life Sciences stock prices, stock quotes, news, and history to help you invest and trade smarter.

Atai Life Sciences (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. In the first week of the new year, the stock plummeted when the failed results of ATAI's NYC-based subsidiary, Perception Neuroscience's Phase 2a study of proprietary R-ketamine PCN-101 on …

Oct 28, 2023 · 1. Atai Life Sciences. With prominent backing from venture capitalists, including billionaire Peter Thiel, it’s not surprising that Atai Life Sciences ranks as one of the biggest biotech stocks ... 0. These 7 analysts have an average price target of $13.29 versus the current price of ATAI Life Sciences at $1.3447, implying upside. Below is a summary of how these 7 analysts rated ATAI Life ...Atai Life Sciences N.V. (NASDAQ: ATAI) is a Germany-based biopharma company focusing on the development of psychedelic drugs. It is placed second on our list of 10 best psychedelic stocks to buy now.Jul 8, 2022 · From July 5 to July 7, the ARK Genomic Revolution ETF purchased 268,974 shares of ATAI Life Sciences (NASDAQ: ATAI). This was the ETF and Ark Invest’s first purchase of ATAI stock since March 14. Find the latest Atari SA (ALATA.PA) stock quote, history, news and other vital information to help you with your stock trading and investing.1.47M. 111.91%. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... On average, Wall Street analysts predict. that Atai Life Sciences Nv's share price could reach $17.50 by Aug 14, 2024. The average Atai Life Sciences Nv stock price prediction forecasts a potential upside of 1,490.91% from the current ATAI share price of $1.10.Nov 29, 2023 · ATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse portfolio of drug candidates in various ... Sarah Popham. Linked companies : Atai Life Sciences N.V. Summary. Presently, Sarah Popham is Vice President-Regulatory Affairs for ATAI Life Sciences NV. She received an undergraduate degree from the University of Bradford. Current …Web

Jun 18, 2021 · Shares of the Peter Thiel -backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling ... Atai Life Sciences N.V. (NASDAQ: ATAI) is a Germany-based biopharma company focusing on the development of psychedelic drugs. It is placed second on our list of 10 best psychedelic stocks to buy now.Meanwhile, Atai listed on the Nasdaq in June, raising $225 million at a valuation of $2.3 billion. The stock immediately popped 40% but it has since halved in value and Atai's current market cap ...Shares of the Peter Thiel -backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling ...Instagram:https://instagram. biggest gambling cities in usbluebirdbio stockmost rarest quarterpru share price Atai Life Sciences has a strong financial position with $227.5 million in cash and funding to support its operations into the 1st half of 2026. The global schizophrenia drug market is expected to ...ATAI Life Sciences N.V. Watch Set a price target alert Premarket Last Updated: Nov 15, 2023 8:18 a.m. EST Delayed quote $ 1.2900 0.04 2.79% Before Hours Volume: 2.23K … ameritrade stock priceheb stocks According to the issued ratings of 4 analysts in the last year, the consensus rating for Atai Life Sciences stock is Buy based on the current 4 buy ratings for ATAI. The average twelve-month price prediction for Atai Life Sciences is $12.80 with a high price target of $20.00 and a low price target of $9.00. Learn more on ATAI's analyst rating ... tiffany fong sam bankman fried (See ATAI stock forecast on TipRanks) SomaLogic . The next Wood pick we’ll look at is a protein biomarker discovery and clinical diagnostics company. SomaLogic operates in what is known as the ...The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions.